KEY WORDS: Leucovorin
; High-dose Methotrexate; Acute Lymphatic Leukemia
After it reaches the con-fluency, the media were then replaced with another media which contain ORAC extract, EIFAM extract, ESFAM extract, 5-flourouracil, and leucovorin
with concentration of 400 ppm, 200 ppm, 100 ppm, 50 ppm, 25 ppm, 12.5 ppm, 6.25 ppm, 3125 ppm, and 15,625 ppm and were then incubated for 24 and 48 h.
49, 4 mos versus 24.0  mos PCR: pathologic complete response; EBRT: external beam radiotherapy; NS: not stated; 5-FU: fluorouracil; LV: leucovorin
; C: cisplatin; P: paclitaxel.
After completion of MTX infusion for 6–8 h, leucovorin
rescue (12 mg, q6h) is started until the serum concentration of MTX falls to 0.05 [micro]mol/L.
USG: Ultrasonography; CS: Cesarean section; CRL: Crown-rump length; EGA: Estimated gestational age; FKA: Fetal cardiac activity; [beta]-hCG: Beta human chorionic gonadotropin; GS: Gestational sac; MTX: Methotrexate; LCV: Leucovorin
; KCI: Potassium chloride
Bevacizumab plus irinotecan, fluorouracil, and leucovorin
for metastatic colorectal cancer.
Bevacizumab is approved for use in first-line therapy in conjunction with either irinotecan- (36) or oxaliplatin-based (37) chemotherapy along with 5-FU and leucovorin
. Ramucirumab is approved for use with FOLFIRI as second-line therapy following progression on first-line 5-FU/capecitabine, oxaliplatin, and bevacizumab.
Randomized phase III study of panitumumab with fluorouracil, leucovorin
, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second line treatment in patients with metastatic colorectal cancer also showed only improvement in PFS of patients with combination therapy (HR=0.73; 95% (CI), 0.59 to 0.90; p=0.004); median PFS was 5.9 months for panitumumab-FOLFIRI versus 3.9 months for FOLFIRI, overall survival has not been changed significantly and median OS was 14.5 months versus 12.5 months, respectively (HR=0.85, 95% (CI), 0.70 to 1.04; p=0.12).
More specifically, in recent studies about chemotherapy, the treatment response rate in colon cancer, which included administration of 5FU/LV (fluorouracil/ leucovorin
) by addition of irinotecan was 22% and led in survival of 6.3 months.
During the past six years Sue has been treated with numerous chemotherapy and biologic treatments including 5-FU, Leucovorin
, Irinotecan (FOLFIRI), Oxaliplatin (FOLFOX), Avastin, and Erbitux by her medical oncologist, Dr.
The relative dose intensity of the chemotherapy regimen was measured by averaging the RDI of each individual drug except for leucovorin
. The RDI for each drug was calculated by multiplying the time index, the time allotted for the administered chemotherapy cycles divided by the duration of said cycles, and the dose index, the administered cumulative dose divided by the standard cumulative dose.
Modufolin is the key active metabolite of all clinically used folate-based drugs used today including Leucovorin